February 2014

  • Ablynx entered into a second research collaboration and licensing agreement with a subsidiary of Merck & Co. (known outside the US and Canada as MSD), which will focus on the discovery and development of several predefined Nanobody candidates directed toward so called “immune checkpoint modulators”, proteins believed to provide potential targets for the development of cancer immunotherapies. Ablynx received an upfront payment of €20 million and is eligible to receive total potential milestone payments of up to €1.7 billion plus tiered royalties.

January 2014

  • Ablynx provided an update on her anti-vWF Nanobody, caplacizumab, to treat acquired thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. Ablynx decided to stop the recruitment of the worldwide Phase II study to allow earlier analysis of the data for potential proof-of-concept. Phase II data are now expected during the first half of 2014.

November 2013

  • Ablynx announced that Sofinnova Partners SAS succesfully completed a private placement of all its Ablynx shares through an accelerated bookbuilding procedure. A total of 3,005,406 shares were placed with institutional investors in both Europe and the United States at €7.26 per share (the last price on 18th November 2013 before the shares were suspended).  

October 2013

  • Ablynx’s partner Boehringer Ingelheim dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody for the treatment of Alzheimer’s disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.
  • Ablynx signed an exclusive, royalty-bearing license agreement with Eddingpharm to develop and commercialise its anti-RANKL Nanobody, ALX-0141, in Greater China, for the treatment osteoporosis and bone metastases.

September 2013

  • Ablynx and Merck Serono further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. Both partners will jointly select disease targets against which this group will develop Nanobodies, up to in vivo proof-of-principle. The dedicated group will focus on the discovery and development of Nanobodies against a number of targets across multiple disease areas. The collaboration will span all of Merck Serono’s core research and development fields, including oncology, immuno-oncology, immunology and neurology.
    The research alliance will have a term of four years, with the option to extend by two and a half years. Research funding from Merck Serono over the first four years will be over €25 million, including an initial payment of €11.5 million at signing, and will aim to ensure that the collaboration could deliver at least six programmes with proof-of-principle in a relevant animal model.
  • Ablynx and AbbVie entered into a global license agreement to develop and commercialise the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases. ALX-0061 is Ablynx’s proprietary anti-IL-6R Nanobody that successfully completed a Phase IIa study in February 2013 reporting strong efficacy and safety data in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.
    Under the terms of the agreement, Ablynx will be responsible for completing Phase II clinical development in both RA and systemic lupus erythematosus (SLE). Upon the achievement of pre-defined success criteria, AbbVie will exercise its right to in-license ALX-0061 and be responsible for subsequent Phase III clinical development and commercialisation. Ablynx will retain an option for co-promotion rights in Belgium, the Netherlands and Luxembourg. Ablynx will receive an upfront payment of $175 million, which will partly be used to fund the next phases of clinical development of ALX-0061. Upon achievement of certain development, regulatory, commercial and sales-based milestones, Ablynx will be eligible to receive additional milestone payments totalling up to $665 million as well as double-digit tiered royalties on net sales upon commercialisation.

July 2013

  • Ablynx initiated two additional Phase I studies with its anti-RSV Nanobody, ALX-0171, with the goal of commencing paediatric development during the second half of 2014. Respiratory Syncytial Virus (RSV) is a respiratory virus that infects the lungs and respiratory tract and is the most common cause of bronchiolitis and pneumonia in children under one year of age. The additional Phase I studies are being performed to determine the appropriate dosing regimen in the subsequent paediatric development of the Nanobody, and will include a safety study in adults with hyper-responsive airways and a local and systemic pharmacokinetic (PK) study in healthy volunteers. The results of both Phase I studies are expected during the first half of 2014.

June 2013

  • Ablynx’s partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of the Nanobody, ALX-0761, for the treatment of inflammatory diseases. ALX-0761 is the first clinical Nanobody candidate to emerge from the collaboration which the companies entered into in 2008. The start of the Phase I study triggers a €2.5 million milestone payment to Ablynx. Ablynx is eligible to receive additional development milestone payments associated with the progress of the product in multiple indications as well as regulatory and commercial milestones plus tiered royalties upon approval of the product.

May 2013

  • Ablynx initiated pre-clinical development of its anti-IgE Nanobody, ALX-0962, for the treatment of severe allergic asthma, with the goal of commencing Phase I clinical development in the second half of 2014. ALX-0962 has been designed to be a potential best-in-class, next generation biologic for the treatment of severe allergic asthma with important potential benefits over available treatment options.

Feb 2013

  • Ablynx successfully raised EUR31.5 million through a private placement.
  • Ablynx announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.
  • Ablynx announced a research collaboration with Spirogen to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen’s proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies generated using Ablynx’s proprietary technology platform.

Nov 2012

  • Ablynx entered into a research collaboration with Algeta to evaluate a novel Targeted Thorium Conjugate (TTC), combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies generated by Ablynx.

Oct 2012

  • Ablynx reported excellent interim results from the Phase I/II study with ALX-0061, the anti-IL-6R Nanobody in patients with RA. These results indicate that ALX-0061 could potential become a best-in-class RA therapeutic.
  • Ablynx entered into a collaboration with Merck & Co., Inc., through a subsidiary, to develop and commercialise Nanobody candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to a second target.

Sept 2012

  • Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company’s forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.
  • Ablynx and its partner Merck Serono advanced Nanobody candidate ALX-0751 in pre-clinical development in the field of oncology.
  • Ablynx announced that it achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.

June 2012

  • Ablynx announced new compelling results on ozoralizumab (ATN-103) in patients with RA.

May 2012

  • Ablynx wins the Trends Gazellen award in the category Mid-Sized Companies, East-Flanders. The “Trends Gazellen 2012″ represent the fastest growing companies for the period 2006-2010.

Apr 2012

  • Ablynx received a €0.4 million milestone payment as Novartis received IND approval for a novel tetrameric Nanobody agonist, TAS266, targeting DR5, a key receptor target on cancer cells across a number of tumour types.

Mar 2012

  • The Strategic Alliance with Boehringer Ingelheim was extended for two years to September 2014, worth an extra €6.6 million to Ablynx.

Feb 2012

  • Boehringer Ingelheim selected, as part of their strategic alliance with Ablynx, a second Nanobody candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of two distinct proteins that are thought to play a major role in human cancers.
  • Ablynx strengthened management team with the appointment of Dr Andreas Menrad as Chief Scientific Officer.

Jan 2012

  • Ablynx was granted extended GMP Certificate for its new Good Manufacturing Practice unit.
Dec 2011

  • Ablynx initiated a Phase I study with ALX-0171, the first inhaled Nanobody for the treatment of RSV infections
  • Ablynx and Merck Serono start pre-clinical development with ALX-0761 in auto-immune disease

Nov 2011

  • ALX-0081 (anti-vWF) didn’t meet the primary endpoint in POC Phase II study
  • Ablynx and Merck Serono expand their partnership into osteoarthritis
  • Ablynx regains rights from Pfizer to Nanobodies targeting TNF-alpha

Jul 2011

  • Ablynx was granted a Good Laboratory Practice (GLP) certificate for its new GLP unit.

Jun 2011

  • Ablynx received a €5 million milestone payment, as part of the Alzheimer’s disease collaboration with Boehringer Ingelheim, following Boehringer Ingelheim’s decision to initiate development with the lead Nanobody candidate that was selected in May 2010.

May 2011

  • Pfizer’s anti-TNF-alpha Nanobody (ATN-103) successfully completes a Phase II study and demonstrates clinical proof-of-concept in patients with rheumatoid arthritis. This is an important breakthrough for the Company as it is the first time that a Nanobody has shown clinical efficacy in a disease setting. This has extremely important implications for Ablynx, the whole Nanobody technology platform and the R&D pipeline.

Mar 2011

  • Ablynx initiated a Phase I/II clinical trial for ALX-0061 in patients with RA.
Dec 2010

  • Ablynx has submitted a request for clinical trials authorization (IMPD) for ALX-0061.
  • Ablynx received further milestone payments totaling €5 million from Boehringer Ingelheim, triggered as Boehringer Ingelheim has selected a Nanobody candidate for further development. Ablynx and Boehringer Ingelheim signed a strategic alliance for the development and commercialisation of Nanobodies in September 2007.

Nov 2010

  • Ablynx received further milestone payments totalling €3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies which was signed in September 2007.
  • Ablynx received a $4m milestone payment from Pfizer for the initiation of a Phase I clinical trial with a second anti-TNFα Nanobody.

Oct 2010

  • Ablynx and Merck Serono entered into a second collaboration to co-discover and co-develop Nanobodies against a single inflammatory disease target.
  • Ablynx received further milestone payments totalling €3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies which was signed in September 2007.

Sep 2010

  • Ablynx opened its first clinical trial centre for an open-label, randomised Phase II study for patients with acquired TTP. This Phase II study will be conducted in Europe and North America and it is planned to enroll over 100 patients.
  • Ablynx announced positive interim data from the ongoing Phase I study in 42 healthy post-menopausal women with ALX-0141, a Nanobody targeting RANKL which plays a key role in bone remodeling.

Jul 2010

  • Novartis obtained licenses from Ablynx to develop and commercialise two novel Nanobodies.
  • Ablynx was awarded a grant worth €1.1 million by the Flemish agency for Innovation by Science and Technology (IWT) and a second grant worth €0.4 million from the Portuguese government, as part of a consortium to explore and develop Nanobody-based therapies for disorders of the central nervous system.

Jun 2010

  • Ablynx won the European Mediscience Award for ‘Best Technology’ for the second year in a row.
  • Ablynx moved into new R&D facilities on the Technologiepark near Ghent, occupying close to 8,000 m².

May 2010

  • Ablynx and Remynd settle dispute amicably.
  • Boehringer Ingelheim selected a lead candidate for development in Alzheimer’s disease.
  • The research collaboration which forms part of its license agreement for Nanobodies to tumour necrosis factor alpha (TNF-alpha) with Pfizer was extended for the third time.

Mar 2010

  • Ablynx advanced ALX-0171, an anti-RSV Nanobody, into pre-clinical development for the treatment of respiratory synctial virus (RSV) infections.
  • Ablynx was successful in raising €50 million with a Secondary Public Offering. The offered shares were priced at €7.5 per share and resulted in 6,666,667 new shares, equivalent to €50 million.

Feb 2010

  • Ablynx successfully opposed a half-life extension patent which had been granted to Domantis. That patent had been revoked in full.

Jan 2010

  • Ablynx reported the successful generation of functional Nanobodies against an ion channel and that it had selected a new Nanobody-based pre-clinical development candidate, ALX-0651, which targets a GPCR called CXCR4.
  • Ablynx announced new data on pulmonary to systemic administration and needle-free administration of Nanobodies.
Dec 2009

  • Ablynx achieved a third milestone payment of €3 million from Boehringer Ingelheim as part of its strategic alliance.

Nov 2009

  • Ablynx was awarded a grant worth €1.1 million by the Flemish agency for Innovation by Science and Technology (IWT) to further develop new routes of administration for Nanobodies.
  • Ablynx achieved a third milestone as part of its drug discovery and development collaboration with Novartis.

Oct 2009

  • Ablynx achieved a milestone payment of €3 million from Boehringer Ingelheim as part of the strategic alliance.
  • Ablynx achieved an undisclosed milestone payment from Novartis for an exclusive research license as part of the R&D alliance.
  • Ablynx reached a settlement with Domantis (part of GSK) concerning a dispute relating to a settlement agreement between Ablynx and Domantis entered into 2005.

Sep 2009

  • Ablynx initiated a Phase II clinical study for ALX-0081 in ACS/PCI.
  • Ablynx received a milestone payment of $4 million as Wyeth Pharmaceuticals (Pfizer) initiated a Phase II multiple dose study of an anti-TNF Nanobody in patients with rheumatoid arthritis.

Jul 2009

  • Ablynx promoted to the Belgian Mid-Cap Index.

Jun 2009

  • Ablynx announced a new preclinical development candidate, ALX-0061, a Nanobody binding to the interleukin-6 receptor (IL6R), for the treatment of autoimmune and inflammatory diseases.

May 2009

  • Ablynx’s vWF Nanobody programme was granted orphan drug designation by both the U.S. Food and Drug Administration and the European Commission for the treatment of thrombotic thrombocytopenic purpura (TTP).

Mar 2009

  • Ablynx reported detailed positive Phase Ib results for ALX-0081 in ACS/PCI.

Feb 2009

  • Ablynx received a $3 million milestone from Boehringer Ingelheim as part of its strategic alliance for the development and commercialisation of Nanobodies.

Jan 2009

  • Ablynx expanded its musculoskeletal research portfolio by transferring in-house full ownership of a bone disorder R&D programme initiated under its collaboration with Procter & Gamble Pharmaceuticals.
  • Ablynx published important initial data on a novel proprietary half-life extension technology and demonstrated the successful pulmonary delivery of Nanobodies.
Dec 2008

  • Wyeth (Pfizer) initiated a first Phase I study in healthy volunteers for Ablynx’s Nanobody targeting tumour necrosis factor alpha (TNF-alpha).
  • Ablynx reported positive results confirming that ALX-0081 (anti-thrombotic) had reached the primary endpoint in a Phase Ib study, demonstrating the desired pharmacological effect.
  • Ablynx initiated its second clinical development programme, ALX-0681. ALX-0681, also an anti-thrombotic which is administered subcutaneously, entered a healthy volunteer Phase I study.

Sep 2008

  • Ablynx and Merck Serono entered into an agreement to co-discover and co-develop Nanobodies against 2 targets in oncology and immunology.

May 2008

  • Ablynx initiated a double-blind, randomized, placebo-controlled multiple dose Phase Ib study for ALX-0081 in patients with stable angina undergoing percutaneous coronary intervention (PCI).study for ALX-0081 in patients with stable angina undergoing percutaneous coronary intervention (PCI).
Dec 2007

  • Ablynx reported the final, positive results from a Phase I study of its lead development programme, ALX-0081 in ACS/PCI.
  • Ablynx raised an additional €10.2 million via an over-allotment option associated with its IPO. Ablynx has now raised a total gross amount of €85.2 million in its initial public offering: €75 million from the placement of new shares and €10.2 million from the over-allotment option.

Nov 2007

  • Ablynx successfully completed its initial public offering (IPO) and listed on Eurolist by Euronext Brussels on November 7th 2007 under the symbol “ABLX”. The IPO was priced at €7.00 per share. Pursuant to the offering, 10,714,285 new shares, equivalent to €75.00 million, were issued by Ablynx, and additionally, 1,607,142 over-allotment shares, equivalent to €11.25 million was allocated.

Sep 2007

  • Boehringer Ingelheim (BI) and Ablynx announced a major global strategic alliance to discover, develop and commercialise up to 10 different Nanobody therapeutics. BI and Ablynx will collaborate jointly in the discovery of Nanobodies against agreed targets across multiple therapeutic areas including immunology, oncology and respiratory disease.

Jun 2007

  • Ablynx reached a second milestone in its collaboration with Procter & Gamble by discovering a second target for possible new treatments in the musculoskeletal area.

Jan 2007

  • Ablynx signed a $265 million exclusive worldwide research and licensing agreement with Boehringer Ingelheim to develop a new Alzheimer’s treatment using Ablynx’s Nanobodies.
Nov 2006

  • Ablynx signed a $212.5 million exclusive worldwide research and licensing agreement with Wyeth (Pfizer) to discover, develop and commercialise Nanbodies directed against TNF-alpha and its receptors.

Oct 2006

  • Ablynx moved into new facilities on the Technologiepark near Ghent, occupying close to 3,000 m². This facility has sufficient space for almost 200 people.

Aug 2006

  • Ablynx raised €40 million (~$50 million) in a series C financing led by new investor KBC, Belgium’s leading bank for private and public equities. SR One, the venture capital arm of GSK was the second new investor. All existing investors (Abingworth, Alta Partners, Gilde, GIMV and Sofinnova Partners) participated in the round which was one of the largest finance rounds in Europe during 2006.

Apr 2006

  • Ablynx and Procter & Gamble Pharmaceuticals extended their discovery and development alliance to include metabolic disease targets.

Mar 2006

  • Edwin Moses, Chairman of Ablynx’s Board of Directors since November 2004, extended his role to also become CEO of Ablynx.

Jan 2006

  • Ablynx and Novartis signed an agreement to collaborate in discovery and development of novel Nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or antibody fragments.
  • Ablynx and Centocor (Johnson&Johnson) signed a collaboration agreement to jointly work on novel approaches for administration and delivery of Nanobody-based therapeutics.
Aug 2005

  • The Opposition Division of the European Patent Office upheld the key composition of matter claims for Nanobodies contained within EP 0 656 946, one of the Hamers Patents, following opposition proceedings initiated by Domantis.
Jul 2004

  • Ablynx and Procter & Gamble Pharmaceuticals entered into a drug discovery and development partnership to discover and develop Nanobody-based drug candidates against a G-protein coupled receptor target specified by Procter & Gamble.

Apr 2004

  • Ablynx closed a series B financing of €25 million led by Alta Partners together with Abingworth. The Company’s existing shareholders GIMV, Sofinnova Partners and Gilde also participated.
Jan 2002

  • Ablynx closed a series A financing of €3 million by Sofinnova and Gilde.
Nov 2001

  • Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.